Art. 14 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 81×
1.

Without prejudice to paragraphs 4 and 5 of this Article and to Article 14-a, a marketing authorisation shall be valid for five years.

2.

The marketing authorisation may be renewed after five years on the basis of a re-evaluation by the Agency of the risk-benefit balance.

To this end, the marketing authorisation holder shall provide the Agency with a consolidated version of the file in respect of quality, safety and efficacy, including the evaluation of data contained in suspected adverse reactions reports and periodic safety update reports submitted in accordance with Chapter 3, and information on all variations introduced since the marketing authorisation was granted, at least 9 months before the marketing authorisation ceases to be valid in accordance with paragraph 1.

3.

Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the Commission decides, on justified grounds relating to pharmacovigilance, including exposure of an insufficient number of patients to the medicinal product concerned, to proceed with one additional five-year renewal in accordance with paragraph 2.

4.

Any authorisation which is not followed by the actual placing of the medicinal product for human use on the Union market within three years after authorisation shall cease to be valid.

5.

When an authorised medicinal product previously placed on the market is no longer actually present on the market for three consecutive years, the authorisation shall cease to be valid.

6.

In exceptional circumstances and on public health grounds the Commission may grant exemptions from paragraphs 4 and 5. Such exemptions must be duly justified.

7.

Following consultation with the applicant, an authorisation may be granted subject to certain specific obligations, to be reviewed annually by the Agency. The list of these obligations shall be made publicly accessible.

By way of derogation from paragraph 1, such authorisation shall be valid for one year, on a renewable basis.

The Commission shall adopt a Regulation laying down provisions for granting such authorisation. That measure, designed to amend non-essential elements of this Regulation by supplementing it, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 87(2a).

8.

In exceptional circumstances and following consultation with the applicant, the marketing authorisation may be granted subject to certain conditions, in particular relating to the safety of the medicinal product, notification to the competent authorities of any incident relating to its use, and action to be taken. The marketing authorisation may be granted only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use, for objective, verifiable reasons and must be based on one of the grounds set out in Annex I to Directive 2001/83/EC. Continuation of the marketing authorisation shall be linked to the annual reassessment of these conditions.

9.

When an application is submitted for a marketing authorisation in respect of medicinal products for human use which are of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure. The request shall be duly substantiated.

If the Committee for Medicinal Products for Human Use accepts the request, the time-limit laid down in Article 6(3), first subparagraph, shall be reduced to 150 days.

10.

When adopting its opinion, the Committee for Medicinal Products for Human Use shall include a proposal concerning the criteria for the prescription or use of the medicinal products in accordance with Article 70(1) of Directive 2001/83/EC.

11.

Without prejudice to the law on the protection of industrial and commercial property, medicinal products for human use which have been authorised in accordance with the provisions of this Regulation shall benefit from an eight-year period of data protection and a ten-year period of marketing protection, in which connection the latter period shall be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorisation holder obtains an authorisation for one or more new therapeutic indications which, during the scientific evaluation prior to their authorisation, are held to bring a significant clinical benefit in comparison with existing therapies.

The 10 that are cited most themselves, of 81.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Article 14(11) of Regulation No 726/2004 provides: ‘Without prejudice to the law on the protection of industrial and commercial property, medicinal products for human use which have been authorised in accordance with the provisions of …

    5 May 2021 · 62018TJ0611

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…3036Law

    … данните, съдържащи се в досието на този продукт в съответствие с член 14, параграф 11 от Регламент (ЕО) № 726/2004 или с член 10 от …

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…Law

    … L’ensemble des modifications du groupe découlent d’une obligation spécifique s’inscrivant dans le cadre de l’article 14, paragraphe 7, du règlement (CE) no 726/2004. 14. L’ensemble des modifications du groupe découlent …

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the Court (Eighth Chamber) of 28 June 2017. Novartis Europharm Ltd v European Commission.Decision

    Article 14(11) of Regulation No 726/2004 provides: ‘Without prejudice to the law on the protection of industrial and commercial property, medicinal products for human use which have been authorised in accordance with the provisions of …

    28 Jun 2017 · 62015CJ0629

  • Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…17Law

    … се прилагат специфични задължения съгласно разпоредбите на член 14, параграф 7 от Регламент (ЕО) № 726/2004, наричани по-долу …

  • SGB 535aLaw

    … bei Arzneimitteln, deren Inverkehrbringen nach dem Verfahren des Artikels 14 Absatz 8 der Verordnung (EG) Nr. 726/2004 des Europäischen Parlaments und des Rates vom 31. März 2004 zur Festlegung der Verfahren der Union für die …

  • Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision

    In support of its action, the applicant puts forward a single plea for annulment, alleging infringement of Article 10(1) of Directive 2001/83 and Article 13(4) of Regulation No 2309/93, read with Articles 14(11) and 89 of Regulation No …

    15 Sep 2015 · 62012TJ0472

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…Lawamends

  • The Human Medicines Regulations 2012146327Law

    … IP completion day, made an application to the EMA for renewal of the EU marketing authorisation in accordance with Article 14 of Regulation (EC) No 726/2004 but no final decision has been made in relation to that application by the …